Long-term use of cancer drug linked to secondary tumours

LONG-TERM use of one of the most common treatments for breast cancer dramatically increases the risk of developing a deadly secondary tumour, a study has shown.

Tamoxifen is the “gold standard” hormonal therapy, given to hundreds of thousands of women to improve their chances of surviving breast cancer.

The drug prevents tumours being fuelled by the sex hormone oestrogen.